 BURNABY, British Columbia, Aug. 23, 2021 GLOBE NEWSWIRE -- Xenon Pharmaceuticals Inc. Nasdaq:XENE, a neurology-focused biopharmaceutical company, today announced the appointment of Christopher Kenney, M.D. as Chief Medical Officer, effective immediately. Dr. Kenney will oversee all clinical development and medical affairs strategies, guiding the development of Xenons portfolio of neurology-focused therapeutic programs. 